Drug
ON 01910 clinical trials
Also written ON 01910.Na, rigosertib and SyB C-1101.
- studies test it
- 36
- open now
- 0
- in phase 3
- 4
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
36 studies that test it; most in 2009 (7)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 2 |
| 2017 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 24
- Phase 2
- 13
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 7
Traws Pharma, Inc. (25) · SymBio Pharmaceuticals (4) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Prof. Johann Bauer (1) · Thomas Jefferson University (1) · Icahn School of Medicine at Mount Sinai (1) · Vanderbilt-Ingram Cancer Center (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Azacitidine (2) · Gemcitabine (2) · Irinotecan (2) · Oxaliplatin (2) · Nivolumab (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses ON 01910 is read from its arms, and is right about nine times in ten.
Testing it · 36
- Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsTerminatedPhase 2Vanderbilt-Ingram Cancer CenterNCT05764395Written as Rigosertib
- Rigosertib for RDEB-SCCCompletedPhase 1/2Prof. Johann BauerNCT03786237Written as Rigosertib Oral Capsules / Rigosertib Intravenous
- Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCCCompletedEarly Phase 1Thomas Jefferson UniversityNCT04177498Written as Rigosertib Sodium
- Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentCompletedPhase 1/2Icahn School of Medicine at Mount SinaiNCT04263090Written as Rigosertib
- Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)CompletedPhase 1SymBio PharmaceuticalsNCT02014051Written as SyB C-1101
- Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic SyndromeWithdrawnPhase 1SymBio PharmaceuticalsNCT02783547Written as SyB C-1101 and Azacytidine
- Study of SyB C-1101 in Patients With Myelodysplastic SyndromeCompletedPhase 1SymBio PharmaceuticalsNCT03495167Written as SyB C-1101
- Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMATerminatedPhase 3Traws Pharma, Inc.NCT02562443Written as rigosertib
- Oral Rigosertib in Low Risk MDS Patients Refractory to ESAsCompletedPhase 2Traws Pharma, Inc.NCT01904682Written as Oral rigosertib
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedPhase 1/2Traws Pharma, Inc.NCT01926587Written as oral rigosertib
- Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaTerminatedPhase 2M.D. Anderson Cancer CenterNCT02730884Written as Rigosertib
- Three Dosing Schedules of Oral Rigosertib in MDS PatientsWithdrawnPhase 1Traws Pharma, Inc.NCT02075034Written as rigosertib
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsCompletedPhase 3Traws Pharma, Inc.NCT01241500Written as ON 01910.Na
- Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedPhase 3Traws Pharma, Inc.NCT01928537Written as rigosertib sodium
- Safety of ON 01910.Na in Patients With MyelodysplasiaCompletedPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT00533416Written as ON 01910 Na
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT00861510Written as ON01910 Na
- Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedPhase 1Traws Pharma, Inc.NCT00854646Written as ON 01910.Na
- Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer PatientsCompletedPhase 2Traws Pharma, Inc.NCT00856791Written as ON 01910.Na
- Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeCompletedPhase 2Traws Pharma, Inc.NCT01584531Written as rigosertib
- Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)CompletedPhase 1/2Traws Pharma, Inc.NCT01167166Written as rigosertib
Codes
What other systems call ON 01910 · ClinicalTrials.gg INT004867
- MeSH (NLM) C507134ON 01910Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 406FL5G00VRIGOSERTIB SODIUMConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C507134 | ON 01910 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 406FL5G00V | RIGOSERTIB SODIUM | Confirmed FDA, NLM |
Also registered as rigosertib (UNII 67DOW7F9GL).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.